IFNA1 and pulmonary arterial hypertension: Indeed, there are many reports on patients undergoing type 1 IFN therapy that develop PAH [43, 43–45] and that the risk of developing PAH is several-fold higher in patients undergoing IFN therapy than in the general population [46].